Physician profile
Amanullah Khan
NPI 1114922531
$1,629.83
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $355 · 2021: $326 · 2022: $285 · 2023: $93.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $220.68 | 2019-2022 | |
| Tactile Systems Technology INC | $132.55 | 2019-2022 | |
| Pfizer INC. | $112.43 | 2019-2022 | |
| Celgene Corporation | $110.81 | 2019-2023 | Pomalyst |
| Merck Sharp & Dohme LLC | $104.52 | 2019-2020 | |
| Astellas Pharma US INC | $98.43 | 2020-2022 | |
| Puma Biotechnology, INC. | $81.55 | 2020-2023 | |
| Incyte Corporation | $63.48 | 2022-2023 | Jakafi |
| Genzyme Corporation | $46.72 | 2020 | |
| Genentech USA, INC. | $42.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.66 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $37.62 | 2020-2021 | |
| Gilead Sciences, INC. | $36.78 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $32.45 | 2019-2020 | |
| Epizyme, INC. | $31.24 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $27.66 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.40 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.86 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $26.71 | 2022 | |
| Medtronic, INC. | $25.96 | 2021-2022 | |
| Daiichi Sankyo INC. | $25.80 | 2023 | Enhertu |
| Abbvie INC. | $24.38 | 2019 | |
| Lilly USA, LLC | $24.20 | 2020-2022 | |
| Myriad Genetic Laboratories, INC. | $21.77 | 2022 | |
| Dova Pharmaceuticals | $20.78 | 2021 | |
| Agios Pharmaceuticals, INC. | $20.46 | 2019 | |
| Amgen INC. | $19.61 | 2021 | |
| Karyopharm Therapeutics INC. | $19.44 | 2020 | |
| Medtronic USA, INC. | $19.42 | 2019 | |
| Blue Earth Diagnostics | $17.81 | 2019 | |
| Mylan Institutional INC. | $16.59 | 2020 | |
| Clovis Oncology, INC. | $16.34 | 2020 | |
| Blueprint Medicines Corporation | $14.71 | 2020 | |
| Dendreon Pharmaceuticals LLC | $14.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.57 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanullah Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.